drugset / Trial / NCT06031597
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Non-randomizedSequentialOpen-labelTreatment
Summary
Patients with stage III non-small-cell lung cancer initially evaluated as unresectable are selected for the program, who are remained unresectable after 2-4 cycles of conversion chemotherapy combined with immune checkpoint inhibitors. Investigators will stratify the treatment according to different performance status scores and radiotherapy plan bi-lung receptor volume to evaluate the safety and efficacy of immunotherapy followed by combined radiotherapy.
Timeline
- Start
- 2023-09-15
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | — |
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |
| Subject | Sugemalimab | Monoclonal antibody | — | — |
| Subject | Tislelizumab | Monoclonal antibody | — | — |
| Background | Cisplatin | Other / unclassified | 25 mg/m2 | — |